Dexcom (DXCM) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.45% |
| Dec 31, 2025 | 12.09% |
| Sep 30, 2025 | 12.70% |
| Jun 30, 2025 | 13.70% |
| Mar 31, 2025 | 19.39% |
| Dec 31, 2024 | 18.96% |
| Sep 30, 2024 | 20.96% |
| Jun 30, 2024 | 28.74% |
| Mar 31, 2024 | 27.43% |
| Dec 31, 2023 | 25.54% |
| Sep 30, 2023 | 32.17% |
| Jun 30, 2023 | 34.22% |
| Mar 31, 2023 | 39.57% |
| Dec 31, 2022 | 38.43% |
| Sep 30, 2022 | 36.57% |
| Jun 30, 2022 | 44.86% |
| Mar 31, 2022 | 51.12% |
| Dec 31, 2021 | 48.39% |
| Sep 30, 2021 | 48.83% |
| Jun 30, 2021 | 48.09% |
| Mar 31, 2021 | 48.06% |
| Dec 31, 2020 | 47.64% |
| Sep 30, 2020 | 50.64% |
| Jun 30, 2020 | 51.31% |
| Mar 31, 2020 | 44.45% |
| Dec 31, 2019 | 44.48% |
| Sep 30, 2019 | 46.05% |
| Jun 30, 2019 | 47.20% |
| Mar 31, 2019 | 49.34% |
| Dec 31, 2018 | 51.14% |
| Sep 30, 2018 | 49.73% |
| Jun 30, 2018 | 46.15% |
| Mar 31, 2018 | 41.78% |
| Dec 31, 2017 | 40.35% |
| Sep 30, 2017 | 36.76% |
| Jun 30, 2017 | 31.11% |
| Mar 31, 2017 | 22.78% |
| Dec 31, 2016 | 22.12% |
| Sep 30, 2016 | 18.28% |
| Jun 30, 2016 | 15.18% |
| Dec 31, 2015 | 29.39% |